-
Mashup Score: 0The Truth About Compounded GLP-1s That Doctors Need to Know - 25 day(s) ago
While counterfeit GLP-1s exist, legitimate compounding pharmacies may also legally make safe ‘copies’ of drugs which are in short supply.
Source: www.mdedge.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1
Both SGLT2 inhibitors and GLP-1 receptor agonists were associated with reduced risk of MACE compared with DPP-4 inhibitors or sulfonylureas. DPP-4 inhibitors were associated with reduced risk of MACE compared with sulfonylureas. There was no statistically significant difference in risk of MACE between SGLT2 inhibitors and GLP-1 receptor agonists. The results provide evidence of the real-world comparative effectiveness of the four most commonly used second-line antihyperglycaemics and could guide choice of antihyperglycaemic therapy.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Comparative effectiveness of #SGLT2 inhibitors, #GLP-1 receptor agonists, #DPP-4 inhibitors, and #sulfonylureas on risk of major adverse #cardiovascular events: emulation of a randomised target trial using electronic health records https://t.co/kgPDb2tPYn #T2D #CVD
-
-
Mashup Score: 3Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history - 7 month(s) ago
The life history theory assumes that all organisms are under selective pressure to harvest external resources and allocate them to maximise fitness: only organisms making the best use of energy obtain the greatest fitness benefits. The trade-off of energy spans four functions: maintenance, growth, reproduction, and defence against pathogens. The innovative antihyperglycaemic agents glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors decrease bodyweight and have the potential to counter low-grade inflammation.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Personal View: #Glucose-lowering #drugs with #cardiovascular benefits as modifiers of critical elements of the human life history https://t.co/FdnQia5S6d #diabetes #obesity #SGLT2 inhibitors #GLP-1 receptor agonists
-
-
Mashup Score: 15
Both SGLT2 inhibitors and GLP-1 receptor agonists were associated with reduced risk of MACE compared with DPP-4 inhibitors or sulfonylureas. DPP-4 inhibitors were associated with reduced risk of MACE compared with sulfonylureas. There was no statistically significant difference in risk of MACE between SGLT2 inhibitors and GLP-1 receptor agonists. The results provide evidence of the real-world comparative effectiveness of the four most commonly used second-line antihyperglycaemics and could guide choice of antihyperglycaemic therapy.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Comparative effectiveness of #SGLT2 inhibitors, #GLP-1 receptor agonists, #DPP-4 inhibitors, and #sulfonylureas on risk of major adverse #cardiovascular events: emulation of a randomised target trial using electronic health records https://t.co/kgPDb2tPYn #T2D #CVD
-
-
Mashup Score: 1Boehringer preps phase 3 for dual-action obesity drug - 8 month(s) ago
Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor dual agonist – partnered with Zealand Pharma and also known as BI 456906 – achieved up to 19% weight loss in people living with overweight or obesity in a study presented at the American Diabetes Association (ADA) congress in June. The two companies are in hot pursuit of Novo Nordisk and Eli Lilly, currently
Source: pharmaphorum.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Announcement that @Boehringer prepares for a phase 3 for dual-action #obesity drug | #pharmaphorum #GLP1 #GLP-1 agonist GLP-1 https://t.co/51HBGFNB8H
-
-
Mashup Score: 2
Both SGLT2 inhibitors and GLP-1 receptor agonists were associated with reduced risk of MACE compared with DPP-4 inhibitors or sulfonylureas. DPP-4 inhibitors were associated with reduced risk of MACE compared with sulfonylureas. There was no statistically significant difference in risk of MACE between SGLT2 inhibitors and GLP-1 receptor agonists. The results provide evidence of the real-world comparative effectiveness of the four most commonly used second-line antihyperglycaemics and could guide choice of antihyperglycaemic therapy.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Comparative effectiveness of #SGLT2 inhibitors, #GLP-1 receptor agonists, #DPP-4 inhibitors, and #sulfonylureas on risk of major adverse #cardiovascular events: emulation of a randomised target trial using electronic health records https://t.co/kgPDb2tPYn #T2D #CVD
-
-
Mashup Score: 9
Both SGLT2 inhibitors and GLP-1 receptor agonists were associated with reduced risk of MACE compared with DPP-4 inhibitors or sulfonylureas. DPP-4 inhibitors were associated with reduced risk of MACE compared with sulfonylureas. There was no statistically significant difference in risk of MACE between SGLT2 inhibitors and GLP-1 receptor agonists. The results provide evidence of the real-world comparative effectiveness of the four most commonly used second-line antihyperglycaemics and could guide choice of antihyperglycaemic therapy.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Comparative effectiveness of #SGLT2 inhibitors, #GLP-1 receptor agonists, #DPP-4 inhibitors, and #sulfonylureas on risk of major adverse #cardiovascular events: emulation of a randomised target trial using electronic health records https://t.co/kgPDb2tPYn #T2D #CVD
-
-
Mashup Score: 0Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history - 1 year(s) ago
The life history theory assumes that all organisms are under selective pressure to harvest external resources and allocate them to maximise fitness: only organisms making the best use of energy obtain the greatest fitness benefits. The trade-off of energy spans four functions: maintenance, growth, reproduction, and defence against pathogens. The innovative antihyperglycaemic agents glucagon-like…
Categories: Endocrinology, Latest HeadlinesTweet-
#Glucose-lowering #drugs with #cardiovascular benefits as modifiers of critical elements of the human life history https://t.co/FdnQia6pVL #diabetes #obesity #GLP-1 receptor agonists #SGLT2 inhibitors https://t.co/hX7xpHmlkY
-
-
Mashup Score: 0
From side effects like nausea to Big Pharma’s influence, some experts caution patients to consider the downsides of drugs like Ozempic and Wegovy.
Source: USA TODAYCategories: Healthcare Professionals, Latest HeadlinesTweet-
This is a very one-sided article that is negative on #GLP-1 agonist medications and is anti-obesity treatment. #GLP1 agonist work to increase the effects of a gut hormone and biological and physiological and are NOT a simple weight loss suppressor. 1/ https://t.co/ZwfjWbuAeD
-
-
Mashup Score: 7Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history - 1 year(s) ago
The life history theory assumes that all organisms are under selective pressure to harvest external resources and allocate them to maximise fitness: only organisms making the best use of energy obtain the greatest fitness benefits. The trade-off of energy spans four functions: maintenance, growth, reproduction, and defence against pathogens. The innovative antihyperglycaemic agents glucagon-like…
Categories: Endocrinology, Latest HeadlinesTweet-
#Glucose-lowering #drugs with #cardiovascular benefits as modifiers of critical elements of the human life history https://t.co/FdnQia5S6d #diabetes #obesity #GLP-1 receptor agonists #SGLT2 inhibitors https://t.co/3aPsXEFWLz
-
While counterfeit #GLP-1s exist, legitimate compounding pharmacies may also legally make safe ‘copies’ of drugs which are in short supply. https://t.co/lwAn9jGfET